Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.
Epistemonikos ID: 60efb62e554a0cc764efbcaac73c11ad594229d0
First added on: Jul 14, 2026